The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
Identifieur interne : 000998 ( Istex/Corpus ); précédent : 000997; suivant : 000999The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
Auteurs : Susan H. Fox ; Regina Katzenschlager ; Shen-Yang Lim ; Bernard Ravina ; Klaus Seppi ; Miguel Coelho ; Werner Poewe ; Olivier Rascol ; Christopher G. Goetz ; Cristina SampaioSource :
- Movement Disorders [ 0885-3185 ] ; 2011-10.
English descriptors
- KwdEn :
- Parkinson's disease, acupuncture, amantadine, anticholinergics, catechol‐O‐methyl transferase inhibitors, clozapine, deep brain stimulation, dopamine agonists, evidence‐based medicine, exercise, levodopa, monoamine oxidase inhibitors, neurosurgery, occupational therapy, physical therapy, speech therapy.
Abstract
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23829
Links to Exploration step
ISTEX:EFC08EE13DB12B91723CF6C75EAAAFDF983AB074Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</mods:affiliation></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation><mods:affiliation>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Lim, Shen Ang" sort="Lim, Shen Ang" uniqKey="Lim S" first="Shen-Yang" last="Lim">Shen-Yang Lim</name><affiliation><mods:affiliation>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EFC08EE13DB12B91723CF6C75EAAAFDF983AB074</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23829</idno><idno type="url">https://api-v5.istex.fr/document/EFC08EE13DB12B91723CF6C75EAAAFDF983AB074/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000998</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000998</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</mods:affiliation></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation><mods:affiliation>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Lim, Shen Ang" sort="Lim, Shen Ang" uniqKey="Lim S" first="Shen-Yang" last="Lim">Shen-Yang Lim</name><affiliation><mods:affiliation>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-10">2011-10</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S41">S41</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">EFC08EE13DB12B91723CF6C75EAAAFDF983AB074</idno><idno type="DOI">10.1002/mds.23829</idno><idno type="ArticleID">MDS23829</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>acupuncture</term><term>amantadine</term><term>anticholinergics</term><term>catechol‐O‐methyl transferase inhibitors</term><term>clozapine</term><term>deep brain stimulation</term><term>dopamine agonists</term><term>evidence‐based medicine</term><term>exercise</term><term>levodopa</term><term>monoamine oxidase inhibitors</term><term>neurosurgery</term><term>occupational therapy</term><term>physical therapy</term><term>speech therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>levodopa</json:string><json:string>dyskinesia</json:string><json:string>placebo</json:string><json:string>uctuations</json:string><json:string>ropinirole</json:string><json:string>entacapone</json:string><json:string>investigational</json:string><json:string>quality score</json:string><json:string>motor complications</json:string><json:string>pramipexole</json:string><json:string>rasagiline</json:string><json:string>randomized</json:string><json:string>rotigotine</json:string><json:string>dopamine</json:string><json:string>agonist</json:string><json:string>selegiline</json:string><json:string>updrs</json:string><json:string>pergolide</json:string><json:string>disord</json:string><json:string>baseline</json:string><json:string>monotherapy</json:string><json:string>cabergoline</json:string><json:string>movement disorders</json:string><json:string>primary outcome measure</json:string><json:string>piribedil</json:string><json:string>specialized monitoring</json:string><json:string>clinical progression</json:string><json:string>acceptable risk</json:string><json:string>pallidotomy</json:string><json:string>amantadine</json:string><json:string>motor symptoms</json:string><json:string>placebo group</json:string><json:string>clozapine</json:string><json:string>neurol</json:string><json:string>bromocriptine</json:string><json:string>dopamine agonists</json:string><json:string>parkinson disease</json:string><json:string>symptomatic adjunct</json:string><json:string>zonisamide</json:string><json:string>speech therapy</json:string><json:string>practice implication</json:string><json:string>other conclusions</json:string><json:string>tolcapone</json:string><json:string>neurology</json:string><json:string>troublesome dyskinesia</json:string><json:string>control group</json:string><json:string>parkinson</json:string><json:string>apomorphine</json:string><json:string>rascol</json:string><json:string>specialized monitoring practice</json:string><json:string>acupuncture</json:string><json:string>anticholinergic</json:string><json:string>subscores</json:string><json:string>qigong</json:string><json:string>dos</json:string><json:string>outcome measures</json:string><json:string>dopaminergic</json:string><json:string>transdermal</json:string><json:string>safety conclusions</json:string><json:string>thalamotomy</json:string><json:string>early disease</json:string><json:string>responder</json:string><json:string>multicenter</json:string><json:string>subthalamic</json:string><json:string>complication</json:string><json:string>nonpharmacological</json:string><json:string>thalamic</json:string><json:string>unilateral pallidotomy</json:string><json:string>lsvt</json:string><json:string>washout</json:string><json:string>lisuride</json:string><json:string>levodopa group</json:string><json:string>stocchi</json:string><json:string>subthalamotomy</json:string><json:string>physical therapy</json:string><json:string>bilateral</json:string><json:string>infusion</json:string><json:string>exercise group</json:string><json:string>levodopa dose</json:string><json:string>occupational therapy</json:string><json:string>arch neurol</json:string><json:string>symptomatic monotherapy</json:string><json:string>clinician</json:string><json:string>other indications</json:string><json:string>carbidopa</json:string><json:string>hauser</json:string><json:string>progression</json:string><json:string>poewe</json:string><json:string>inclusion criteria</json:string><json:string>entacapone group</json:string><json:string>nonergot</json:string><json:string>rcts</json:string><json:string>clinical practice</json:string><json:string>neurosurg</json:string><json:string>dopamine agonist</json:string><json:string>practice implications</json:string><json:string>melevodopa</json:string><json:string>secondary outcome measures</json:string><json:string>pramipexole group</json:string><json:string>comt</json:string><json:string>medication</json:string><json:string>surgical</json:string><json:string>symptomatic adjunct therapy</json:string><json:string>comparator</json:string><json:string>active comparator</json:string><json:string>cochrane</json:string><json:string>antiparkinsonian</json:string><json:string>safety issues</json:string><json:string>deep brain stimulation</json:string><json:string>rotigotine transdermal patch</json:string><json:string>ongoing</json:string><json:string>gray backgrounds</json:string><json:string>duodenal</json:string><json:string>white backgrounds</json:string><json:string>noninferiority</json:string><json:string>follett</json:string><json:string>subscore</json:string><json:string>hazard ratio</json:string><json:string>primary outcome</json:string><json:string>randomised</json:string><json:string>sumanirole</json:string><json:string>inhibitor</json:string><json:string>updrs scores</json:string><json:string>total updrs</json:string><json:string>primary outcome measures</json:string><json:string>neurol neurosurg psychiatry</json:string><json:string>secondary outcomes</json:string><json:string>treatment groups</json:string><json:string>disease patients</json:string><json:string>ropinirole group</json:string><json:string>therapy</json:string><json:string>adjunct</json:string><json:string>treadmill</json:string><json:string>control groups</json:string><json:string>subgroup analysis</json:string><json:string>other dopamine agonists</json:string><json:string>rotigotine group</json:string><json:string>motor function</json:string><json:string>parkinson study group</json:string><json:string>levodopa therapy</json:string><json:string>disease progression</json:string><json:string>surgery group</json:string><json:string>large number</json:string><json:string>total updrs score</json:string><json:string>responder rate</json:string><json:string>washout period</json:string><json:string>selegiline group</json:string><json:string>aerobic</json:string><json:string>crossover</json:string><json:string>conventional therapy</json:string><json:string>patient diaries</json:string><json:string>implications treatments</json:string><json:string>impulse control disorders</json:string><json:string>sample size</json:string><json:string>other outcome measures</json:string><json:string>unilateral thalamotomy</json:string><json:string>unilateral subthalamotomy</json:string><json:string>movement strategy training</json:string><json:string>other therapies</json:string><json:string>treadmill training</json:string><json:string>brain stimulation</json:string><json:string>placebo hours</json:string><json:string>points points</json:string><json:string>disease duration</json:string><json:string>aerobic training</json:string><json:string>intervention group</json:string><json:string>greater improvement</json:string><json:string>qigong group</json:string><json:string>randomized trial</json:string><json:string>levodopa treatment</json:string><json:string>early parkinson disease</json:string><json:string>adjunct therapy</json:string><json:string>safety practice</json:string><json:string>motor complications treatment</json:string><json:string>unilateral</json:string><json:string>median</json:string><json:string>symptom</json:string><json:string>implication</json:string><json:string>disorder</json:string></teeft></keywords><author><json:item><name>Susan H. Fox MRCP (UK), PhD</name><affiliations><json:string>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</json:string><json:string>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</json:string></affiliations></json:item><json:item><name>Regina Katzenschlager MD</name><affiliations><json:string>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Shen‐Yang Lim MD, FRACP</name><affiliations><json:string>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</json:string></affiliations></json:item><json:item><name>Bernard Ravina MD, MS</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Klaus Seppi MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Miguel Coelho MD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>evidence‐based medicine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>monoamine oxidase inhibitors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>catechol‐O‐methyl transferase inhibitors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>amantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anticholinergics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clozapine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurosurgery</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>deep brain stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>exercise</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>physical therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>speech therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>occupational therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>acupuncture</value></json:item></subject><articleId><json:string>MDS23829</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>2173</abstractCharCount><pdfWordCount>28846</pdfWordCount><pdfCharCount>187192</pdfCharCount><pdfPageCount>40</pdfPageCount><abstractWordCount>271</abstractWordCount></qualityIndicators><title>The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>26</volume><issue>S3</issue><pages><first>S2</first><last>S41</last><total>40</total></pages><genre><json:string>journal</json:string></genre><author><json:item><name>Susan H. Fox</name></json:item><json:item><name>Klaus Seppi</name></json:item><json:item><name>Cristina Sampaio</name></json:item></author><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23829</json:string></doi><id>EFC08EE13DB12B91723CF6C75EAAAFDF983AB074</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/EFC08EE13DB12B91723CF6C75EAAAFDF983AB074/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/EFC08EE13DB12B91723CF6C75EAAAFDF983AB074/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/EFC08EE13DB12B91723CF6C75EAAAFDF983AB074/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2011 Movement Disorder Society</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Reviewed and approved by the International Executive Committee of the Movement Disorder Society. Funding agencies: This work was supported by the MDS and an unrestricted educational grant from Teva Pharmaceuticals. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Susan H.</forename><surname>Fox</surname></persName><roleName type="degree">MRCP (UK), PhD</roleName><affiliation>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</affiliation></author><author xml:id="author-2"><persName><forename type="first">Regina</forename><surname>Katzenschlager</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</affiliation></author><author xml:id="author-3"><persName><forename type="first">Shen‐Yang</forename><surname>Lim</surname></persName><roleName type="degree">MD, FRACP</roleName><affiliation>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</affiliation></author><author xml:id="author-4"><persName><forename type="first">Bernard</forename><surname>Ravina</surname></persName><roleName type="degree">MD, MS</roleName><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation></author><author xml:id="author-5"><persName><forename type="first">Klaus</forename><surname>Seppi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author xml:id="author-6"><persName><forename type="first">Miguel</forename><surname>Coelho</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-7"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author xml:id="author-8"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</affiliation></author><author xml:id="author-9"><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author xml:id="author-10"><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-10"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S41">S41</biblScope></imprint></monogr><idno type="istex">EFC08EE13DB12B91723CF6C75EAAAFDF983AB074</idno><idno type="DOI">10.1002/mds.23829</idno><idno type="ArticleID">MDS23829</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>evidence‐based medicine</term></item><item><term>levodopa</term></item><item><term>dopamine agonists</term></item><item><term>monoamine oxidase inhibitors</term></item><item><term>catechol‐O‐methyl transferase inhibitors</term></item><item><term>amantadine</term></item><item><term>anticholinergics</term></item><item><term>clozapine</term></item><item><term>neurosurgery</term></item><item><term>deep brain stimulation</term></item><item><term>exercise</term></item><item><term>physical therapy</term></item><item><term>speech therapy</term></item><item><term>occupational therapy</term></item><item><term>acupuncture</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02-03">Received</change><change when="2011-05-13">Registration</change><change when="2011-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/EFC08EE13DB12B91723CF6C75EAAAFDF983AB074/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="115"><doi origin="wiley" registered="yes">10.1002/mds.v26.3s</doi><titleGroup><title type="supplementTitle">Evidence‐Based Medicine</title></titleGroup><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">S3</numbering><numbering type="supplement" number="S3">S3</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Susan H.</givenNames><familyName>Fox</familyName></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName></personName></creator></creators><coverDate startDate="2011-10">October 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23829</doi><idGroup><id type="unit" value="MDS23829"></id></idGroup><countGroup><count type="pageTotal" number="40"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-03"></event><event type="manuscriptAccepted" date="2011-05-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.10 mode:FullText" date="2011-10-21"></event><event type="firstOnline" date="2011-10-21"></event><event type="publishedOnlineFinalForm" date="2011-10-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S2</numbering><numbering type="pageLast">S41</numbering></numberingGroup><correspondenceTo>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23829.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="8"></count><count type="referenceTotal" number="120"></count><count type="wordTotal" number="31824"></count></countGroup><titleGroup><title type="main" xml:lang="en">The <i>Movement</i> Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease<link href="#fn3"></link></title><title type="short" xml:lang="en">Treatment of Motor Symptoms in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Susan H.</givenNames><familyName>Fox</familyName><degrees>MRCP (UK), PhD</degrees></personName><contactDetails><email>sfox@uhnresearch.ca</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Regina</givenNames><familyName>Katzenschlager</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Shen‐Yang</givenNames><familyName>Lim</familyName><degrees>MD, FRACP</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Bernard</givenNames><familyName>Ravina</familyName><degrees>MD, MS</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Miguel</givenNames><familyName>Coelho</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="MY" type="organization"><unparsedAffiliation>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="PT" type="organization"><unparsedAffiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="FR" type="organization"><unparsedAffiliation>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">evidence‐based medicine</keyword><keyword xml:id="kwd3">levodopa</keyword><keyword xml:id="kwd4">dopamine agonists</keyword><keyword xml:id="kwd5">monoamine oxidase inhibitors</keyword><keyword xml:id="kwd6">catechol‐<i>O</i>‐methyl transferase inhibitors</keyword><keyword xml:id="kwd7">amantadine</keyword><keyword xml:id="kwd8">anticholinergics</keyword><keyword xml:id="kwd9">clozapine</keyword><keyword xml:id="kwd10">neurosurgery</keyword><keyword xml:id="kwd11">deep brain stimulation</keyword><keyword xml:id="kwd12">exercise</keyword><keyword xml:id="kwd13">physical therapy</keyword><keyword xml:id="kwd14">speech therapy</keyword><keyword xml:id="kwd15">occupational therapy</keyword><keyword xml:id="kwd16">acupuncture</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Reviewed and approved by the International Executive Committee of the <i>Movement</i> Disorder Society.</p><p><b>Funding agencies:</b> This work was supported by the MDS and an unrestricted educational grant from Teva Pharmaceuticals.</p><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of Motor Symptoms in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Susan H.</namePart><namePart type="family">Fox</namePart><namePart type="termsOfAddress">MRCP (UK), PhD</namePart><affiliation>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario, Canada</affiliation><affiliation>Movement Disorder Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, Canada M5V 2S8</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Regina</namePart><namePart type="family">Katzenschlager</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shen‐Yang</namePart><namePart type="family">Lim</namePart><namePart type="termsOfAddress">MD, FRACP</namePart><affiliation>Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Ravina</namePart><namePart type="termsOfAddress">MD, MS</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Miguel</namePart><namePart type="family">Coelho</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-10</dateIssued><dateCaptured encoding="w3cdtf">2011-02-03</dateCaptured><dateValid encoding="w3cdtf">2011-05-13</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">8</extent><extent unit="references">120</extent><extent unit="words">31824</extent></physicalDescription><abstract lang="en">The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society</abstract><note type="content">*Reviewed and approved by the International Executive Committee of the Movement Disorder Society. Funding agencies: This work was supported by the MDS and an unrestricted educational grant from Teva Pharmaceuticals. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>evidence‐based medicine</topic><topic>levodopa</topic><topic>dopamine agonists</topic><topic>monoamine oxidase inhibitors</topic><topic>catechol‐O‐methyl transferase inhibitors</topic><topic>amantadine</topic><topic>anticholinergics</topic><topic>clozapine</topic><topic>neurosurgery</topic><topic>deep brain stimulation</topic><topic>exercise</topic><topic>physical therapy</topic><topic>speech therapy</topic><topic>occupational therapy</topic><topic>acupuncture</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Susan H.</namePart><namePart type="family">Fox</namePart></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart></name><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>S3</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>S3</number></detail><extent unit="pages"><start>S2</start><end>S41</end><total>40</total></extent></part></relatedItem><identifier type="istex">EFC08EE13DB12B91723CF6C75EAAAFDF983AB074</identifier><identifier type="DOI">10.1002/mds.23829</identifier><identifier type="ArticleID">MDS23829</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000998 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000998 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:EFC08EE13DB12B91723CF6C75EAAAFDF983AB074
|texte= The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |